January 16, 2026
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Tyler Howes
| Re: | Immix Biopharma, Inc. | ||
| Registration Statement on Form S-3 | |||
Filed January 9, 2026 |
|||
| File No: 333-292665 |
Dear Mr. Howes,
Immix Biopharma, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-292665), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Tuesday, January 20, 2026, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow, Esq. and Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
| Very truly yours, | ||
| IMMIX BIOPHARMA, INC. | ||
| By: | /s/ Gabriel Morris | |
| Name: | Gabriel Morris | |
| Title: | Chief Financial Officer | |
| cc: | Leslie Marlow, Esq., Blank Rome LLP | |
| Melissa Murawsky, Esq., Blank Rome LLP |